Regenxbio (RGNX) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Regenxbio (RGNX) over the last 10 years, with Q3 2025 value amounting to -$1.2.
- Regenxbio's EPS (Weighted Average and Diluted) fell 256.41% to -$1.2 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year increase of 3107.57%. This contributed to the annual value of -$4.59 for FY2024, which is 2386.48% up from last year.
- Per Regenxbio's latest filing, its EPS (Weighted Average and Diluted) stood at -$1.2 for Q3 2025, which was down 256.41% from -$1.38 recorded in Q2 2025.
- Over the past 5 years, Regenxbio's EPS (Weighted Average and Diluted) peaked at $6.7 during Q4 2021, and registered a low of -$1786.6 during Q1 2022.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$1.39 (2022), whereas its average is -$263.05.
- Within the past 5 years, the most significant YoY rise in Regenxbio's EPS (Weighted Average and Diluted) was 63981.95% (2021), while the steepest drop was 14889920.12% (2021).
- Over the past 5 years, Regenxbio's EPS (Weighted Average and Diluted) (Quarter) stood at $6.7 in 2021, then tumbled by 120.76% to -$1.39 in 2022, then decreased by 3.7% to -$1.44 in 2023, then grew by 28.16% to -$1.04 in 2024, then decreased by 15.88% to -$1.2 in 2025.
- Its EPS (Weighted Average and Diluted) was -$1.2 in Q3 2025, compared to -$1.38 in Q2 2025 and $0.12 in Q1 2025.